Juzina

Sitagliptin, the active ingredient in Juzina, is a DPP‑4 inhibitor presented as a tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to lower elevated blood glucose levels when used together with diet and exercise. It is available in standard tablet strengths and is manufactured under strict GMP conditions.

GNH USA supplies Juzina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing consistent quality and regulatory compliance for global distribution across multiple regions and therapeutic markets.

Sitagliptin is used in the management of type 2 diabetes mellitus, acting on the incretin pathway to improve glycemic control. - Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels as part of a comprehensive treatment plan. - Type 2 diabetes mellitus (combination therapy with metformin): provides additional HbA1c reduction when added to metformin. - Type 2 diabetes mellitus (adjunct to diet and exercise): assists patients in achieving target glycemic goals alongside lifestyle modifications.

Sitagliptin may be associated with a range of adverse reactions, most of which are mild and transient. Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient cranial pain. - Gastrointestinal discomfort: nausea or abdominal pain. Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain indicating possible pancreatic inflammation. - Severe allergic reactions: rash, angioedema or anaphylaxis. - Joint pain: unexplained arthralgia.

When prescribing sitagliptin, clinicians should consider several safety aspects to minimise risk. - Renal impairment: dose adjustment or avoidance is recommended in patients with reduced kidney function. - Hepatic impairment: use with caution in patients with liver disease and monitor liver enzymes. - Concomitant sulfonylureas or insulin: increased risk of hypoglycaemia; monitor blood glucose closely. - Elderly patients: may be more susceptible to adverse effects; start at the lowest effective dose. - Cardiovascular risk: assess for history of heart failure, although no direct contraindication. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Sitagliptin can interact with other medicines, altering its efficacy or safety profile. Major Interactions (Avoid): - Co‑administration with strong DPP‑4 inhibitors (e.g., saxagliptin): may increase risk of adverse effects; avoid simultaneous use. - Combined use with insulin or sulfonylureas: can cause severe hypoglycaemia; dose adjustments required. Moderate Interactions (Monitor Closely): - Rifampin: induces metabolism and may reduce sitagliptin plasma levels, decreasing effectiveness. - Diuretics (e.g., thiazides): may enhance hypoglycaemic effect; monitor glucose. - ACE inhibitors or ARBs: potential additive effect on blood pressure; observe patient response.